This brand name is authorized in Japan, Spain.
The drug BONALFA contains one active pharmaceutical ingredient (API):
1
|
UNII
B3Q63NVN9R - TACALCITOL MONOHYDRATE
|
|
Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| D05AX04 | Tacalcitol | D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| ES | Centro de información online de medicamentos de la AEMPS | 62312 |
| JP | 医薬品医療機器総合機構 | 2691700M1053, 2691700M2025, 2691700N1059, 2691700Q1047, 2691700Q2027 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.